Solutions
About Us
Insights
Careers

SPIRIT-DEFINE explanation and elaboration: recommendations for enhancing quality and impact of early phase dose-finding clinical trials protocols. Ursino M, Villacampa G, Rekowski J, Dimairo M, Solovyeva O, Ashby D, Berlin J, Boix O, Calvert M, Chan AW, Coschi CH, Evans TRJ, Garrett-Mayer E, Golub RM, Guo C, Hayward KS, Hopewell S, Isaacs JD, Ivy SP, Jaki T, Kholmanskikh O, Kightley A, Lee S, Liu R, Mander A, Marshall LV, Matcham J, Patel D, Peck R, Rantell KR, Richards DP, Rouhifard M, Seymour L, Tanaka Y, Weir CJ, de Bono J, Yap C. EClinicalMedicine. 2025

CONSORT-DEFINE explanation and elaboration: recommendations for enhancing reporting quality and impact of early phase dose-finding clinical trials. Rekowski J, Guo C, Solovyeva O, Dimairo M, Rouhifard M, Patel D, Alger E, Ashby D, Berlin J, Boix O, Calvert M, Chan AW, Coschi CH, de Bono J, Evans TRJ, Garrett-Mayer E, Golub RM, Hayward KS, Hopewell S, Isaacs JD, Ivy SP, Jaki T, Kholmanskikh O, Kightley A, Lee S, Liu R, Maia I, Mander A, Marshall LV, Matcham J, Peck R, Rantell KR, Richards DP, Seymour L, Tanaka Y, Ursino M, Weir CJ, Yap C. EClinicalMedicine. 2025

A Phase II Open-Label, Randomized Clinical Trial of Atezolizumab with or without Human Recombinant IL-7 (CYT107) in Advanced Urothelial Cancer. Sweis RF, Chatta GS, Jain RK, Moon H, Delacroix SE, Fang A, D’Amico L, Kask AS, Cheever MA, Fling S, Sharon E, Lacroix A, Kaiser JC, Pachynski RK, Yu EY. Clin Cancer Res. 2025

Testing One Primary and Two Secondary Endpoints in a Two-Stage Group Sequential Trial With Extensions. Tamhane AC, Xi D, Mehta CR, Romanenko A, Gou J. Stat Med. 202

The effect of prenatal balanced energy and protein supplementation on gestational weight gain: An individual participant data meta-analysis in low- and middle-income countries. Wang D, Partap U, Liu E, Costa JC, Cliffer IR, Wang M, Nookala SK, Subramoney V, Briggs B, Ahmed I, Argaw A, Ariff S, Bhandari N, Chowdhury R, Erchick D, García-Guerra A, Ghaffarpour M, Hanley-Cook G, Huybregts L, Jehan F, Kaseb F, Krebs NF, Lachat C, Lama TP, Manandhar DS, McClure EM, Moore SE, Muhammad A, Neufeld LM, Prentice AM, Quezada-Sánchez AD, Roberfroid D, Saville NM, Shafiq Y, Shrestha BP, Sonko B, Soofi S, Taneja S, Tielsch JM, Toe LC, Valaei N, Fawzi WW. PLoS Med. 2025

Long-Term Safety and Efficacy of Esmethadone in Patients With Major Depressive Disorder: Findings From a 12-Month Open-Label Study. Fava M, Pani L, De Martin S, Cutler AJ, Gorodetzky CW, Vocci FJ, Sapienza FL, Kosten TR, Kröger C, Champasa P, Guidetti C, Comai S, Mattarei A, Folli F, Bushnell D, Traversa S, Inturrisi CE, Manfredi PL, Pappagallo M. J Clin Psychiatry. 2025

Phase I study of efineptakin alfa (NT-I7) for the treatment of Kaposi sarcoma. Ramaswami R, Kask AS, D’Amico L, Menon MP, Lurain K, Yarchoan R, Ekwede I, Couey P, Burnham E, Angeldekao A, Ha Lee B, Kaiser JC, Cheever M, Uldrick TS, Kwok LL, Wright A, Fling SP, Wang CJ. J Immunother Cancer. 2025

Matching-Adjusted Indirect Comparison of Daratumumab-Pomalidomide-Dexamethasone and Pomalidomide-Bortezomib-Dexamethasone in Relapsed/Refractory Multiple Myeloma. Chng WJ, Wu DB, Wu CK, Springford A, Daly CH, Jung SH. Clin Lymphoma Myeloma

Serum levels of hepatitis B core antibodies and hepatitis B core-related antigen at the time of nucleos(t)ide analog cessation and risk of severe flares in patients with chronic hepatitis B. van Bömmel F, Verbinnen T, Agarwal K, Vanwolleghem T, Lampertico P, Buti M, Janczewska E, Bourliere M, Jezorwski J, Donohue K, Kim G, Kakuda TN, De Meyer S, Bakala A, Biermer M, Lenz O. Hepatol Commun. 2025

Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study. Wiendl H, Barkhof F, Montalban X, Achiron A, Derfuss T, Chan A, Hodgkinson S, Prat A, Leocani L, Schmierer K, Sellebjerg F, Vermersch P, Jin H, Chudecka A, Kloetgen A, Lin D, Gardner L, De Stefano N. Front Immunol. 2025